Home / Products / Formulations / Svizera Healthcare / Ace / Camforte



  Composition :
  Each tablet of CAMFORTE contains:
  Cabergoline.....0.25 mg/0.5mg
  Therapeutic Indications & Usage
  CAMFORTE is indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.
  CAMFORTE is contraindicated in uncontrolled hypertension, known hypersensitivity to ergot derivatives or to its ingredients. It is not indicated for the inhibition or suppression of physiologic lactation.
  Cabergoline (CAMFORTE) should not be administered concurrently with Dantagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
  Dopamine Agonists in General should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia and eclampsia, unless the potential benefit is judged to outweigh the possible risk.Since cabergoline is extensively metabolized by the liver, caution should be used and careful monitoring done if CAMFORTE is advocated in hepatic impairment.
  Doses of Cabergoline (CAMFORTE) higher than 1 mg may produce hypotension. Care should be exercised when administering cabergoline with other medications known to lower blood pressure. Patients should be instructed to notify her physician if she suspects she is pregnant, becomes pregnant or intends to become pregnant during therapy. A pregnancy test should be done if there is any suspicion of pregnancy and continuation of CAMFORTE treatment should be discussed with her physician.
  In lactation, a decision must be taken to withdraw cabergoline (CAMFORTE) or discontinue lactation, depending on the importance of the drug to the mother. Safety and effectiveness of cabergoline (CAMFORTE) have not been established in children.
  Adverse Reactions
  Cabergoline (CAMFORTE) can cause hypersensitivity reactions, asthenia, fatigue, influenza-like symptoms, malaise, hot flushes, edema, weight changes, dry mouth, gastrointestinal intolerance, central nervous symptoms, somnolence, depression, nervousness, anxiety, impaired concentration, postural hypotension, syncope, palpitations, rarely heart failure and constrictive pericarditis, breast pain, dysmenorrhea, musculoskeletal pains, skin lesions, respiratory affections and abnormal vision.
  Drug Interactions :
  Cabergoline (CAMFORTE) should not be administered concurrently with Dantagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
  Recommended Dosage & Administration
  0.25 CAMFORTE Tab twice a week. Dosage may be increased by 0.25 CAMFORTE Tab twice weekly upto a maximum dosage of 1 mg CAMFORTE Tabs twice weekly according to the patient's serum prolactin level. The increase in dose must be not more than once in 4 weeks.
  After a normal serum prolactin level has been maintained for 6 months cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when the CAMFORTE treatment should be re-instituted.
  CAMFORTE®:0.25/0.5 Tablets: Strip of 2s
  Pack Shot of Camforte Range
"Maneesh" Pharmaceuticals   |  Manufacturing Excellence  |   International Presence  |  Products
"Maneesh" for Doctors  |  Our Team  |  For the Patients  
Contact Us  |  Feedback  |  Site Map  | Search Maneesh